The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

The funding was meant to help the U.S. prepare for pandemics triggered by avian flu strains, but now leaves the future of ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.